Active Litigation
Kratom Lawsuit Facts
TorHoerman Law is investigating claims for the Kratom Lawsuit.
Active Litigation
TorHoerman Law is investigating claims for the Kratom Lawsuit.
A kratom liver damage lawsuit may involve drug-induced liver injury, jaundice, cholestatic hepatitis, or liver failure allegedly associated with a kratom product.
Medical studies have documented patients who developed serious liver abnormalities within weeks of beginning kratom use, including cases requiring hospitalization.
Most patients described in published reports improved after stopping kratom, but severe cases have involved prolonged liver dysfunction and transplantation.
TorHoerman Law is investigating potential claims involving serious liver injuries allegedly associated with kratom products and inadequate product warnings.

Kratom comes from Mitragyna speciosa, a tropical evergreen tree native to Southeast Asia, and is sold as powders, capsules, teas, extracts, and other formulations.
Some consumers use kratom for pain relief, stimulant effects, or opioid withdrawal symptoms, while others use it for recreational purposes; the FDA has not approved kratom for any medical purpose.
The liver processes many compounds absorbed from medications, botanical products, and other substances, and some exposures can interfere with normal liver health.
Kratom-associated liver injuries have most often involved impaired bile flow, liver cell damage, or a combination of the two.
Affected patients may develop fatigue and nausea before more recognizable signs such as itching, dark urine, and yellowing of the eyes or skin.
The medical evidence supports an association between kratom use and clinically important liver injury, but it does not establish how often these reactions occur or whether a particular product caused an individual injury.
Our attorneys are reviewing potential claims involving severe jaundice, hepatitis, acute liver failure, and injuries requiring transplant evaluation.
Broader information about eligibility, manufacturers, and legal procedures is available through our kratom lawsuit investigation.
Call TorHoerman Law today for a free consultation, or use the chat feature on this page to discuss a potential kratom liver injury claim.
Yes, the use of kratom has been linked to drug-induced liver injury (DILI), including cases assessed by liver specialists as probably, highly likely, or definitely related to kratom exposure.
According to the NIH LiverTox reference on kratom, reported injury usually begins within one to eight weeks after starting regular use.
LiverTox describes predominantly cholestatic or mixed injury, sometimes with substantial bilirubin elevations and prolonged jaundice.
Liver injury has occurred after relatively brief exposure, and neither high doses nor prolonged use have been established as prerequisites for a serious reaction.
The principal patterns of liver injury reported with kratom include:
These categories describe how an injury presents in clinical tests, not three separate proven mechanisms by which kratom necessarily causes damage.
The one-to-eight-week window reported by LiverTox describes the usual onset among published cases after regular use begins, not a fixed period outside which liver injury is impossible.
In a U.S. Drug-Induced Liver Injury Network study, symptoms began a median of 14 days after starting kratom, and laboratory evidence appeared after a median of 21 days.
Individual cases have involved different products, other medications, and varying histories of use.
A patient may also have abnormal liver tests before noticing jaundice or other symptoms.
Because the onset can be relatively rapid, a person who develops dark urine, itching, or yellowing of the eyes after beginning kratom should seek medical evaluation rather than assuming the symptoms are unrelated.
The precise biological mechanism responsible for kratom-related liver injury has not been established.
Some cases appear consistent with an idiosyncratic reaction, meaning liver damage can arise in a susceptible person without a predictable relationship to the amount consumed.
Kratom products also vary in alkaloid content, formulation, and other ingredients, complicating comparisons between patients.
Laboratory studies suggest that certain kratom alkaloids can affect enzymes involved in metabolizing medications, but those findings do not prove that a specific drug interaction caused every reported liver injury.
Factors clinicians consider when evaluating possible contributors include:
A temporal association supports investigation, but it is not a substitute for evaluating other causes of liver disease.
Concentrated extracts and enhanced 7-hydroxymitragynine (7-OH) products can differ substantially from conventional kratom leaf in their active-compound content.
The FDA has separately warned about concentrated 7-OH products, particularly their opioid-like effects and potential health risks.
However, human liver injury reports do not establish whether extracts or enhanced 7-OH formulations carry greater liver risks than conventional kratom leaf; ongoing research is needed.
When a liver injury occurs, identifying the exact product and its ingredients is more informative than assuming every kratom formulation carries the same risks.
The most useful clinical evidence includes structured assessments of suspected drug-induced liver injury and reviews of published case reports.
These sources document serious reactions but cannot determine the incidence of liver injury among everyone who uses kratom.
A study published in Drug and Alcohol Dependence identified eleven cases of kratom-associated liver injury in a prospective U.S. cohort using structured causality assessments.
The cases were identified within the Drug-Induced Liver Injury Network (DILIN), a U.S. research program examining suspected medication- and supplement-related liver injuries.
The researchers reported the following findings:
Ten patients recovered completely within six months, while the remaining patient had mildly elevated liver tests that normalized within one year.
There were no deaths or liver transplants in this 11-patient series.
The study offers comparatively strong case-level evidence because clinicians assessed competing explanations, but it does not establish how frequently liver injury occurs in the broader population of kratom users.
A systematic review published in the Journal of Addiction Medicine examined 31 studies describing 32 patients with kratom-associated liver injury.
Most publications involved individual case reports, and several patients had other medical conditions or used additional substances.
The review found that jaundice and elevated liver enzymes were common, with cholestatic injury the predominant reported pattern.
Most patients improved after kratom use stopped, but four published cases progressed to liver transplantation.
Only seven of the 32 cases included complete details about product form, dose, frequency, and duration of use.
The four transplant cases document the possibility of severe outcomes; they do not establish that one in eight kratom users with liver injury will need a transplant.
Publication bias, incomplete exposure histories, and inconsistent causality assessments limit conclusions about the overall risk.
Some case reports provide additional evidence through tissue findings or the return of symptoms after renewed exposure.
A 2018 case report in Gastroenterology Research described a patient with dark-colored urine and pale stools whose liver biopsy showed acute cholestatic injury after kratom use.
His reported laboratory abnormalities included elevated ALT, alkaline phosphatase, and bilirubin, and his condition improved following discontinuation.
A separate case report published in Hepatology described jaundice and liver abnormalities that recurred after kratom was restarted.
A recurrence following renewed exposure can strengthen a suspected causal connection, although intentionally restarting a product after a serious liver reaction is not recommended as a diagnostic test.
Liver injury may initially cause nonspecific symptoms, and some abnormalities are first detected through blood testing.
The combination of itching, dark urine, pale stools, and jaundice is especially relevant to the cholestatic patterns reported in kratom cases.
Symptoms warranting medical assessment include:
These physical symptoms may also occur with gallstones, viral hepatitis, medication reactions, or other health problems; diarrhea or abdominal pain alone is not evidence of liver damage.
Dark urine can have nonhepatic causes, including dehydration or blood in the urine, so its appearance alone does not establish liver damage.
Severe liver injury may impair the liver’s ability to perform essential functions rather than merely increasing enzyme levels.
Acute liver failure can involve abnormal blood clotting and altered mental status in a person without preexisting advanced liver disease.
Seek emergency medical care for warning signs such as:
A very high ALT level does not by itself establish acute liver failure, and a patient can have severe cholestasis with substantial bilirubin elevation without meeting the criteria for liver failure.
There is no single laboratory test that definitively identifies kratom as the cause of a liver injury.
Healthcare practitioners evaluate the timing of kratom use alongside blood tests, other possible causes, and the course of the illness after exposure stops.
The American Association for the Study of Liver Diseases (AASLD) guidance on drug-induced liver injury recommends reviewing medication and supplement histories and excluding alternative explanations.
Tests used in a liver injury evaluation may include:
Clinicians may use the relationship between ALT and ALP elevations to classify an injury as hepatocellular, cholestatic, or mixed.
A worsening INR or new confusion can indicate a more serious clinical problem than an isolated enzyme elevation.
A useful medical history includes when the patient started kratom, whether the product or amount changed, when symptoms began, and when laboratory abnormalities were first documented.
It should also account for alcohol, acetaminophen taken above recommended doses, prescription medications, other supplements, viral illnesses, and preexisting liver conditions, rather than attributing every abnormal result to kratom.
Improvement after kratom discontinuation can support a suspected association, but it is not conclusive proof of causation.
A biopsy or imaging result may establish the type of liver injury without identifying which product or substance produced it.
Treatment is guided by the injury pattern, its severity, and whether another condition is contributing to the abnormal findings.
When kratom is suspected of causing liver damage, healthcare practitioners generally recommend stopping the product and avoiding repeat exposure while evaluating the condition.
Medical management may involve:
The NIH LiverTox resource notes that corticosteroids and N-acetylcysteine have been used in some reported kratom cases, but their effectiveness specifically for kratom-related liver injury has not been established.
Those treatments should not be described as proven remedies for kratom hepatotoxicity.
People who have developed dependence from regular kratom use may also experience withdrawal symptoms after stopping; clinicians can address those separately from the liver injury.
Many patients in the published literature improved after stopping kratom, although recovery may take weeks or months.
Cholestatic injury can be prolonged because bilirubin and bile-flow abnormalities sometimes resolve more slowly than liver enzymes.
Follow-up blood tests help monitor liver health, determine whether bilirubin and enzyme levels are returning toward normal, and identify complications requiring further treatment.
The DILIN study reported recovery in all 11 patients, whereas the 2026 review documented four published cases requiring liver transplantation.
These different outcomes cannot be used to calculate a reliable recovery or transplant rate among all kratom users.
Patients who receive a liver transplant generally require long-term follow-up and medications to prevent rejection.
Severe liver illness may occur alongside acute kidney injury, particularly when dehydration, low blood pressure, or multiorgan dysfunction complicates the patient’s condition.
LiverTox describes acute kidney failure in some severe kratom-associated liver injury reports, but kidney injury can have several simultaneous causes.
A liver injury diagnosis should not automatically be treated as proof of direct kratom toxicity to the kidneys.
The FDA has not approved kratom to treat pain, opioid withdrawal, opioid use disorder, or any other medical condition.
The agency’s warnings provide safety context but do not establish that a particular product caused an individual’s liver injury or that any company is liable.
Our attorneys are reviewing potential claims involving severe jaundice, drug-induced hepatitis, prolonged liver dysfunction, acute liver failure, and liver transplantation following kratom use.
The relevant medical questions include the diagnosed injury, the timing of kratom exposure, any other medications or medical conditions, and whether a particular product may have contributed to the patient’s illness.
Medical reports documenting kratom-associated liver injury do not automatically establish a legally actionable defect or inadequate warning.
The kratom lawsuit parent page addresses potential defendants, evidence, filing deadlines, and compensation in greater detail.
Call TorHoerman Law today or contact our firm for a free consultation. You can also use the chat feature on this page.
NIH LiverTox reports that symptoms of kratom-associated liver injury usually develop within one to eight weeks after beginning regular use.
The DILIN study documented a median of 14 days to symptom onset, but an individual case may follow a different timeline.
These findings do not establish a safe period of kratom use or a dose that prevents liver injury.
Yes.
Jaundice reflects elevated bilirubin and may occur with cholestatic or mixed liver injury even when a patient does not have acute liver failure.
Clinicians also assess blood clotting, mental status, laboratory trends, and other findings when determining severity.
Not necessarily.
Elevated liver enzymes can arise from other medications, viral infections, alcohol-related injury, metabolic liver disease, and other causes.
The timing of kratom use, the pattern of laboratory abnormalities, and evaluation for alternative causes help determine whether an association is plausible.
Severe drug-induced liver injury can cause prolonged dysfunction, and rare published kratom-associated cases have required liver transplantation.
Most reported patients improved after stopping kratom, including all 11 patients in the DILIN cohort.
The available studies do not establish how frequently permanent liver damage occurs among people who use kratom.
No established dose or duration of kratom use reliably predicts who will develop drug-induced liver injury.
In the prospective DILIN cohort, symptoms appeared after a median of 14 days, so serious reactions were documented without years of heavy use.
A person’s medical history, concurrent medications, and the particular product may affect the assessment, but the current research cannot quantify how these factors change an individual’s risk.
Recurrent jaundice and liver abnormalities after renewed kratom exposure have been described in a published case report.
That history supports avoiding a suspected causative product rather than attempting to test the association through reexposure.
Someone with a previous suspected drug-induced liver injury should discuss further exposure and follow-up testing with a healthcare professional.
Current human research does not establish equivalent liver risks across conventional kratom leaf, concentrated extracts, and products containing enhanced 7-OH.
Products differ in composition, and many published liver injury cases do not document the exact formulation or amount consumed.
The specific product and other exposures should be considered when evaluating suspected liver toxicity.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Kratom Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.